Cramer's 'Mad Money' Recap: Why the Data Didn't Matter

On Monday, Cramer said he'll be watching two great recent initial public offerings, Palo Alto Networks (PANW), a cyber security play, and Five Below (FIVE), a discount retailer. Shares of Palo Alto are up 33% from their after market IPO price, while shares of Five Below are up 30%. Cramer said both companies remain strong buys.

Tuesday brings United Natural Foods (UNFI), earnings that should reignite interest in Whole Foods (WFM) and Hain Celestial (HAIN). Cramer advised using any weakness on Monday to pick up shares in these names.

Then on Wednesday, it's Apple's turn to take center stage with an expected iPhone announcement. Cramer said if the new device has a "wow factor," shares of Apple will continue to soar. But if the product is only slightly cooler, then look for shares to dive.

For Thursday, Cramer said he'll be watching Pier 1 Imports (PIR), a company he's confident can deliver on its numbers.

In non-stock news, Cramer said he'll also be keeping eyes on the U.S. Department of Agriculture crop report on Wednesday, a report that should bolster seed makers Monsanto (MON) and DuPont (DD).

He also awaits the German court ruling on whether that country can participate in the European bail out. Then on Thursday, it's the G-20 Summit, along with the Fed, that will have investors glued to their seats.

Bulls vs. Bears

"Normally, I stay away from battleground stocks," Cramer told viewers, but sometimes you have to take sides. He was talking about Questcor Pharmaceuticals (QCOR), a stock that's had a remarkable seven-year run from just 50 cents a share to $52 a share.

Cramer explained that unlike many smaller drug makers, Questcor is not playing "FDA roulette," hoping for approval on a host of new drugs. Instead, the company has just one drug, Acthar gel, which it is now marketed for 19 different ailments, with more on the way.

At issue is the battle between the bulls and the bears, said Cramer. The turbulence started in July, when several Web sites began reporting rumors that generic competition for Acthar was on the way. That sent shares spiraling, something that benefited the 44% of the company's shares that were sold short at the time.

« First ‹ Previous 1 2 3 4 Next › Last »